CINECA IRIS Institutional Research Information System

MOLINARO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.242
EU - Europa 4.477
AS - Asia 3.609
SA - Sud America 555
AF - Africa 227
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.116
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.061
DE - Germania 1.609
SG - Singapore 1.155
CN - Cina 997
IT - Italia 757
SE - Svezia 643
HK - Hong Kong 525
BR - Brasile 458
GB - Regno Unito 416
VN - Vietnam 278
BG - Bulgaria 219
AT - Austria 201
FR - Francia 149
RU - Federazione Russa 138
TR - Turchia 138
CA - Canada 130
IN - India 114
FI - Finlandia 99
JP - Giappone 92
CI - Costa d'Avorio 91
SN - Senegal 68
UA - Ucraina 64
KR - Corea 63
BD - Bangladesh 50
NL - Olanda 38
AR - Argentina 32
IQ - Iraq 28
MX - Messico 26
MA - Marocco 25
PL - Polonia 25
PK - Pakistan 22
CH - Svizzera 21
BE - Belgio 20
UZ - Uzbekistan 18
VE - Venezuela 18
ZA - Sudafrica 18
ES - Italia 17
CO - Colombia 16
ID - Indonesia 14
SA - Arabia Saudita 14
PH - Filippine 13
EC - Ecuador 12
IR - Iran 10
GR - Grecia 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 8
LT - Lituania 8
MY - Malesia 8
JM - Giamaica 7
NP - Nepal 7
TN - Tunisia 7
CZ - Repubblica Ceca 6
IL - Israele 6
JO - Giordania 6
CL - Cile 5
CY - Cipro 5
EE - Estonia 5
EG - Egitto 5
IE - Irlanda 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
HU - Ungheria 4
KE - Kenya 4
KG - Kirghizistan 4
LB - Libano 4
RS - Serbia 4
UY - Uruguay 4
AL - Albania 3
AU - Australia 3
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
PY - Paraguay 3
BZ - Belize 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MK - Macedonia 2
PA - Panama 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
Totale 16.104
Salva come PNG Salva come JPEG
Città #
Ashburn 851
Dallas 685
Singapore 629
Hong Kong 519
Woodbridge 514
San Jose 461
Fairfield 436
Chandler 413
Santa Clara 413
Ann Arbor 311
Houston 277
Sofia 219
Shanghai 218
Milan 215
New York 210
Seattle 205
Beijing 200
Vienna 186
Cambridge 172
Wilmington 159
Los Angeles 146
London 109
Princeton 104
Boardman 103
Munich 96
Abidjan 91
Ottawa 85
Lawrence 83
Lauterbourg 77
Tokyo 75
Jacksonville 69
Dakar 68
Hefei 68
Frankfurt am Main 66
Pisa 65
Florence 64
Medford 61
Ho Chi Minh City 60
Izmir 59
Seoul 56
Hanoi 55
Istanbul 48
Serra 47
Bremen 44
Dearborn 43
Rome 41
Des Moines 40
Nanjing 40
Redondo Beach 38
Dong Ket 36
São Paulo 35
Buffalo 33
San Diego 32
Council Bluffs 28
Helsinki 26
Orem 25
Boulder 23
Turku 23
Columbus 22
Düsseldorf 22
Ogden 21
Redwood City 20
Brussels 19
Redmond 19
Chicago 18
Lancaster 18
Nanchang 18
Nürnberg 17
Chennai 16
Denver 16
Fuzhou 16
Guangzhou 16
Rio de Janeiro 16
Tashkent 16
Amsterdam 15
Changsha 15
San Francisco 15
Atlanta 14
Montreal 14
Pune 14
Quanzhou 14
Baghdad 13
Belo Horizonte 13
Bern 13
Toronto 13
Warsaw 13
Casablanca 12
Norwalk 12
Stockholm 12
Zhengzhou 12
Brooklyn 11
Da Nang 11
Jüchen 11
Kunming 11
Washington 11
Jiaxing 10
Nuremberg 10
Philadelphia 10
Poplar 10
Chengdu 9
Totale 10.163
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 318
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 289
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 259
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 254
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 253
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 253
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 239
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 234
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 233
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 226
Targeted Therapy in Thyroid Cancer: State of the Art 224
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 222
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 219
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 215
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 215
RET point mutations in Thyroid Carcinoma 208
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 204
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 204
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 197
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 196
mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study 196
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 196
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 194
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 192
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 187
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 183
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 179
Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations 178
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 177
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 176
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 173
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 169
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 169
Thyroid consequences of the Chernobyl nuclear accident. 168
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 167
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 167
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 159
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 159
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 158
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 156
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer 156
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 155
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 155
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 155
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 150
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. 150
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 149
null 146
Carcinoma tiroideo e gravidanza. 144
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 144
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 142
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 138
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 137
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 134
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 133
Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance 132
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 132
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 131
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 129
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 127
Papillary thyroid microcarcinoma: Toward an active surveillance strategy 125
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 123
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 121
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 119
Ablazione del residuo tiroideo post chirurgico con rhTSH e 30 mCi. 119
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 116
null 114
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 113
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 113
null 107
null 105
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 105
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 104
null 103
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 102
Single thyroid nodule 101
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 100
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 97
Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test 90
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 89
Il carcinoma della tiroide 89
Tako-tsubo Syndrome as First Manifestation in a Case of Pheochromocytoma Developed From a Non-functional Adrenal Incidentaloma 87
null 84
Ret Oncogene and Thyroid Carcinoma 81
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. 71
null 70
Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. 60
Totale 16.196
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.892
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.038 33 35 12 81 221 130 39 41 56 55 63 272
2022/20231.738 214 290 159 147 155 184 33 118 314 9 104 11
2023/20241.067 110 106 132 63 131 205 86 49 12 19 50 104
2024/20253.370 39 126 37 204 366 312 230 178 362 431 340 745
2025/20264.050 317 612 498 414 416 300 563 165 215 362 126 62
2026/202714 14 0 0 0 0 0 0 0 0 0 0 0
Totale 16.287